



Cancer Genetics and Genomics

Guest Editors:

Dr. Ovidiu Balacescu

Department of Genetics,
Genomics and Experimental
Pathology, The Oncology
Institute "Prof. Dr. Ion Chiricuta",
400015 Cluj-Napoca, Romania

Dr. Adrian Pavel Trifa

Department of Genetics, "Iuliu
Hatieganu" University of
Medicine and Pharmacy, Cluj-
Napoca, Romania and The
Oncology Institute "Prof. Dr. Ion
Chiricuta", 400015 Cluj-Napoca,
Romania

Deadline for manuscript
submissions:
closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Cancer is one of the most complex diseases, and its early diagnosis and effective treatment is a permanent challenge. Both genomic and genetic approaches have decisively contributed to a better characterization of the malignant phenotype, the discovery of new biomarkers, and targeted therapies, especially with the advent of new technologies such as next-generation sequencing at both DNA and RNA levels. However, new data are necessary to complete the big puzzle of molecular alterations that underlie cancer development and its treatment resistance. Moreover, new insight into cancer–host cohabitation needs to be decoded in order to better understand if and how the corrupted host cells could be targeted to improve cancer treatment management.

One useful approach in cancer management is to use liquid biopsy for identifying new biomarkers such as specific methylation or mutation patterns, or the presence of gene expression alteration of circulating RNAs (miRNAs, circRNAs, lncRNAs).

As Guest Editors of this Special Issue, we cordially invite you to contribute one or more research or review papers focused on genomic or genetic approaches in cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)